Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Acta Diabetologica
Erschienen in: Acta Diabetologica 3/2012

01.06.2012 | Review Article

The potential role of glutamate in the current diabetes epidemic

verfasst von: Alberto M. Davalli, Carla Perego, Franco B. Folli

Erschienen in: Acta Diabetologica | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

In the present article, we propose the perspective that abnormal glutamate homeostasis might contribute to diabetes pathogenesis. Previous reports and our recent data indicate that chronically high extracellular glutamate levels exert direct and indirect effects that might participate in the progressive loss of β-cells occurring in both T1D and T2D. In addition, abnormal glutamate homeostasis may impact all the three accelerators of the “accelerator hypothesis” and could partially explain the rising frequency of T1D and T2D.
Literatur
1.
Gale EA (2009) The rise of childhood type 1 diabetes in the 20th century. Diabetes 51(12):3353–3361CrossRef
2.
Harjutsalo V, Sjöberg L, Tuomilehto J (2008) Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 371(9626):1777–1782PubMedCrossRef
3.
Karvonen M, Pitkaniemi J, Tuomilehto J (1999) The onset age of type 1 diabetes in Finnish children has become younger. The Finnish childhood diabetes registry group. Diabetes Care 22(7):1066–1070
4.
Kitagawa T, Owada M, Urakami T, Yamauchi K (1998) Increased incidence of non-insulin dependent diabetes mellitus among Japanese schoolchildren correlates with an increased intake of animal protein and fat. Clin Pediatr (Phila) 37(2):111–115CrossRef
5.
Dabelea D, DeGroat J, Sorrelman C, Glass M, Percy CA, Avery C, Hu D, D’Agostino RB Jr, Beyer J, Imperatore G, Testaverde L, Klingensmith G, Hamman RF; SEARCH for Diabetes in Youth Study Group (2009) Diabetes in Navajo youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care 32(suppl 2):S141–147
6.
Braun B, Zimmermann MB, Kretchmer N, Spargo RM, Smith RM, Gracey M (1999) Risk factors for diabetes and cardiovascular disease in young Australian aborigines. A 5-year follow-up study. Diabetes Care 19(5):472–479
7.
Drake AJ, Smith A, Betts PR, Crowne EC, Shield JP (2002) Type 2 diabetes in obese white children. Arch Dis Child 86(3):207–208PubMedCrossRef
8.
Gallwitz B, Kazda C, Kraus P, Nicolay C, Schernthaner G (2011) Contribution of insulin deficiency and insulin resistance to the development of type 2 diabetes: nature of early stage diabetes. Acta Diabetol Aug 23 [Epub ahead of print] PubMed PMID: 21861172
9.
Carnevale Schianca GP, Colli E, Onolfo S, Pedrazzoli R, Fra GP, Bartoli E (2010) Individuation of different metabolic phenotypes in normal glucose tolerance test. Acta Diabetol 47(2):167–172PubMedCrossRef
10.
Kanat M, Norton L, Winnier D, Jenkinson C, DeFronzo RA, Abdul-Ghani MA (2011) Impaired early- but not late-phase insulin secretion in subjects with impaired fasting glucose. Acta Diabetol 48(3):209–217PubMedCrossRef
11.
Mølbak AG, Christau B, Marner B, Borch-Johnsen K, Nerup J (1994) Incidence of insulin-dependent diabetes mellitus in age groups over 30 years in Denmark. Diabet Med 11(7):650–655PubMedCrossRef
12.
Rosenbloom AL, Joe JR, Young RS, Winter WE (1999) Emerging epidemic of type 2 diabetes in youth. Diabetes Care 22(2):345–354PubMedCrossRef
13.
Aizawa T, Funase Y, Katakura M, Asanuma N, Yamauchi K, Yoshizawa K, Hashizume K (1997) Ketosis-onset diabetes in young adults with subsequent non-insulin-dependency, a link between IDDM and NIDDM? Diabet Med 14(11):989–991PubMedCrossRef
14.
Brooks-Worrell BM, Reichow JL, Goel A, Ismail H, Palmer JP (2011) Identification of autoantibody-negative autoimmune type 2 diabetic patients. Diabetes Care 34(1):168–173PubMedCrossRef
15.
Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R (1997) UKPDS 25: antibodies to islet cell and GAD for prediction of insulin requirement in type 2 diabetes. UK prospective diabetes study group. Lancet 350(9087):1288–1293PubMedCrossRef
16.
Unnikrishnan AG, Singh SK, Sanjeevi CB (2004) Prevalence of GAD65 antibodies in lean subjects with type 2 diabetes. Ann NY Acad Sci 1037:118–121PubMedCrossRef
17.
Hathout EH, Thomas W, El-Shahawy M, Nahab F, Mace JW (2001) Diabetic autoimmune markers in children and adolescents with type 2 diabetes. Pediatrics 107:E102PubMedCrossRef
18.
Umpaichitra V, Banerji MA, Castells S (2002) Autoantibodies in children with type 2 diabetes mellitus. J Pediatr Endocrinol Metab 15:525–530PubMed
19.
Hypponen E, Virtanen SM, Kenward MG, Knip M, Akerblom HK (2000) Obesity, increased linear growth, and risk of type 1 diabetes in children. Diabetes Care 23(12):1755–1760PubMedCrossRef
20.
Libman IM, Pietropaolo M, Arslanian SA, LaPorte RE, Becker DJ (2003) Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes. Diabetes Care 26(10):2871–2875PubMedCrossRef
21.
Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC (2004) Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 47(10):1661–1667PubMedCrossRef
22.
Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11(2):98–107PubMedCrossRef
23.
Wang AP, Li X, Zheng Y, Liu BL, Huang G, Yan X, Liu Z, Zhou Z. (2010) Thiazolidinediones protect mouse pancreatic beta-cells directly from cytokine-induced cytotoxicity through PPAR-gamma-dependent mechanisms. Acta Diabetol Dec 10 [Epub ahead of print] PubMed PMID: 21153483
24.
Mandrup-Poulsen T, Zumsteg U, Reimers J, Pociot F, Mørch L, Helqvist S, Dinarello CA, Nerup J (1993) Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic beta-cell destruction in insulin-dependent diabetes mellitus. Cytokine 5(3):185–191PubMedCrossRef
25.
Pickersgill LM, Mandrup-Poulsen TR (2009) The anti-interleukin-1 in type 1 diabetes action trial–background and rationale. Diabetes Metab Res Rev 25(4):321–324PubMedCrossRef
26.
Sanda S, Bollyky J, Standifer N, Nepom G, Hamerman JA, Greenbaum C (2010) Short-term IL-1beta blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes. Clin Immunol 136(2):170–173PubMedCrossRef
27.
Sumpter KM, Adhikari S, Grishman EK, White PC (2011) Preliminary studies related to anti-interleukin-1β therapy in children with newly diagnosed type 1 diabetes. Pediatr Diabetes 12(7):656–667PubMedCrossRef
28.
Wilkin TJ (2001) The Accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes. Diabetologia 44(7):914–922PubMedCrossRef
29.
Raha O, Chowdhury S, Dasgupta S, Raychaudhuri P, Sarkar BN, Raju PV, Rao VR (2009) Approaches in type 1 diabetes research: a status report. Int J Diabetes Dev Ctries 29(2):85–101PubMedCrossRef
30.
Blachier F, Boutry C, Bos C, Tomé D (2009) Metabolism and functions of L-glutamate in the epithelial cells of the small and large intestines. Am J Clin Nutr 90(3):814S–821SPubMedCrossRef
31.
Matthews DE, Marano MA, Campbell RG (1993) Splanchnic bed utilization of glutamine and glutamic acid in humans. Am J Physiol 264(6):E848–E854PubMed
32.
Solimena M, Folli F, Denis-Donini S, Comi GC, Pozza G, De Camilli P, Vicari AM (1998) Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med 318(16):1012–1020CrossRef
33.
Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olesen H, De Camilli P (1990) Identification of the 64 K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347(6289):151–156PubMedCrossRef
34.
Reetz A, Solimena M, Matteoli M, Folli F, Takei K, De Camilli P (1991) GABA and pancreatic beta-cells: colocalization of glutamic acid decarboxylase (GAD) and GABA with synaptic-like microvesicles suggests their role in GABA storage and secretion. EMBO J 10(5):1275–1284PubMed
35.
MacMullen C, Fang J, Hsu BY, Kelly A, de Lonlay-Debeney P, Saudubray JM, Ganguly A, Smith TJ, Stanley CA (2001) Hyperinsulinism/hyperammonemia contributing Investigators Hyperinsulinism/hyperammonemia syndrome in children with regulatory mutations in the inhibitory guanosine triphosphate-binding domain of glutamate dehydrogenase. J Clin Endocrinol Metab 86(4):1782–1787PubMedCrossRef
36.
Maechler P, Wollheim CB (1999) Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis. Nature 402(6762):685–689PubMedCrossRef
37.
Lau A, Tymianski M (2010) Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch 460(2):525–542PubMedCrossRef
38.
Julio-Pieper M, Flor PJ, Dinan TG, Cryan JF (2011) Exciting times beyond the brain: metabotropic glutamate receptors in peripheral and non-neural tissues. Pharmacol Rev 63(1):35–58PubMedCrossRef
39.
Guemez-Gamboa A, Estrada-Sánchez AM, Montiel T, Páramo B, Massieu L, Morán J (2011) Activation of NOX2 by the stimulation of ionotropic and metabotropic glutamate receptors contributes to glutamate neurotoxicity in vivo through the production of reactive oxygen species and calpain activation. J Neuropathol Exp Neurol 70(11):1020–1035PubMedCrossRef
40.
41.
Bertrand G, Gross R, Puech R, Loubatières-Mariani MM, Bockaert J (1992) Evidence for a glutamate receptor of the AMPA subtype which mediates insulin release from rat perfused pancreas. Br J Pharmacol 106(2):354–359
42.
Bertrand G, Gross R, Puech R, Loubatières-Mariani MM, Bockaert J (1993) Glutamate stimulates glucagon secretion via an excitatory amino acid receptor of the AMPA subtype in rat pancreas. Eur J Pharmacol 237(1):45–50PubMedCrossRef
43.
Gonoi T, Mizuno N, Inagaki N, Kuromi H, Seino Y, Miyazaki J, Seino S (1994) Functional neuronal ionotropic glutamate receptors are expressed in the non-neuronal cell line MIN6. J Biol Chem 269(25):16989–16992PubMed
44.
Inagaki N, Kuromi H, Gonoi T, Okamoto Y, Ishida H, Seino Y, Kaneko T, Iwanaga T, Seino S (1995) Expression and role of ionotropic glutamate receptors in pancreatic islet cells. FASEB J 9(8):686–691PubMed
45.
Weaver CD, Yao TL, Powers AC, Verdoorn TA (1996) Differential expression of glutamate receptor subtypes in rat pancreatic islets. J Biol Chem 271(22):12977–12984PubMedCrossRef
46.
Weaver CD, Gundersen V, Verdoorn TA (1998) A high affinity glutamate/aspartate transport system in pancreatic islets of Langerhans modulates glucose-stimulated insulin secretion. J Biol Chem 273(3):1647–1653PubMedCrossRef
47.
Brice NL, Varadi A, Ashcroft SJ, Molnar E (2002) Metabotropic glutamate and GABA(B) receptors contribute to the modulation of glucose-stimulated insulin secretion in pancreatic beta cells. Diabetologia 45(2):242–252PubMedCrossRef
48.
Tong Q, Ouedraogo R, Kirchgessner AL (2002) Localization and function of group III metabotropic glutamate receptors in rat pancreatic islets. Metab 282(6):E1324–E1333
49.
50.
Lerner J (1987) Acidic amino acid transport in animal cells and tissues. Comp Biochem Physiol B 87(3):443–457PubMedCrossRef
51.
Moe AJ (1995) Placental amino acid transport. Am J Physiol 268(6):C1321–C1331PubMed
52.
Schneider H, Möhlen KH, Dancis J (1979) Transfer of amino acids across the in vitro perfused human placenta. Pediatr Res 13(4):236–240PubMedCrossRef
53.
Johanson CE (1980) Permeability and vascularity of the developing brain: cerebellum vs cerebral cortex. Brain Res 190(1):3–16PubMedCrossRef
54.
Kniesel U, Wolburg H (2000) Tight junctions of the blood-brain barrier. Cell Mol Neurobiol 20(1):57–76PubMedCrossRef
55.
Hermanussen M, Tresguerres JA (2003) Does the thrifty phenotype result from chronic glutamate intoxication? A hypothesis. J Perinat Med 31(6):489–495PubMedCrossRef
56.
Faus O, López Morales J, Faus MJ, Periago JL, Bueno Sánchez A, Gil A, Martínez Valverde A (1984) Free amino acid content of human milk in Spain. An Esp Pediatr 21(6):557–563PubMed
57.
Agostoni C, Carratù B, Boniglia C, Lammardo AM, Riva E, Sanzini E (2000) Free glutamine and glutamic acid increase in human milk through a three-month lactation period. J Pediatr Gastroenterol Nutr 31(5):508–512PubMedCrossRef
58.
Agostoni C, Carratù B, Boniglia C, Riva E, Sanzini E (2000) Free amino acid content in standard infant formulas: comparison with human milk. J Am Coll Nutr 19(4):434–438PubMed
59.
DeSantiago S, Ramírez I, Tovar AR, Alonso L, Ortíz-Olaya N, Torres N (1998) Free amino acids in plasma and milk of mexican rural lactating women. Rev Invest Clin 50(5):405–412PubMed
60.
Villalpando S, Butte NF, Flores-Huerta S, Thotathuchery M (1998) Qualitative analysis of human milk produced by women consuming a maize-predominant diet typical of rural Mexico. Ann Nutr Metab 42(1):23–32PubMedCrossRef
61.
Otabe S, Nakayama H, Fukutani T, Yuan X, Wada N, Hashinaga T, Mitsui A, Kato T, Inada C, Tajiri Y, Yamada K (2010) Excessive maternal transmission of diabetes in Japanese families with young-onset type 2 diabetes and insulin secretion defect according to clinical features. Acta Diabetol 47(suppl 1):133–138PubMedCrossRef
62.
Choi DW, Maulucci-Gedde M, Kriegstein AR (1987) Glutamate neurotoxicity in cortical cell culture. J Neurosci 7(2):357–368PubMed
63.
Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, Kanai Y, Hediger MA, Wang Y, Schielke JP, Welty DF (1996) Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16(3):675–686PubMedCrossRef
64.
Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, Iwama H, Nishikawa T, Ichihara N, Kikuchi T, Okuyama S, Kawashima N, Hori S, Takimoto M, Wada K (1997) Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276(5319):1699–1702PubMedCrossRef
65.
Pizzi WJ, Barnhart JE (1976) Effects of monosodium glutamate on somatic development, obesity and activity in the mouse. Pharmacol Biochem Behav 5(5):551–557PubMedCrossRef
66.
Iwase M, Yamamoto M, Iino K, Ichikawa K, Shinohara N, Yoshinari M, Fujishima M (1998) Obesity induced by neonatal monosodium glutamate treatment in spontaneously hypertensive rats: an animal model of multiple risk factors. Hypertens Res 21(1):1–6PubMedCrossRef
67.
Roman-Ramos R, Almanza-Perez JC, Garcia-Macedo R, Blancas-Flores G, Fortis-Barrera A, Jasso EI, Garcia-Lorenzana M, Campos-Sepulveda AE, Cruz M, Alarcon-Aguilar FJ (2011) Monosodium glutamate neonatal intoxication associated with obesity in adult stage is characterized by chronic inflammation and increased mRNA expression of peroxisome proliferator-activated receptors in mice. Basic Clin Pharmacol Toxicol 108(6):406–413PubMedCrossRef
68.
Sasaki Y, Suzuki W, Shimada T, Iizuka S, Nakamura S, Nagata M, Fujimoto M, Tsuneyama K, Hokao R, Miyamoto K, Aburada M (2009) Dose dependent development of diabetes mellitus and non-alcoholic steatohepatitis in monosodium glutamate-induced obese mice. Life Sci 85(13–14):490–498PubMedCrossRef
69.
Islam MS, Loots du T (2009) Experimental rodent models of type 2 diabetes: a review. Methods Find Exp Clin Pharmacol 31(4):249–261PubMed
70.
Nagata M, Suzuki W, Iizuka S, Tabuchi M, Maruyama H, Takeda S, Aburada M, Miyamoto K (2006) Type 2 diabetes mellitus in obese mouse model induced by monosodium glutamate. K Exp Anim 55(2):109–115CrossRef
71.
Anantharaman K (1972) In utero and dietary administration of monosodium l-glutamate to mice: reproductive performance and development in a multigeneration study. In: Filer LJ Jr, Garattini S, Kare MR, Reynolds WA, Wurtman RJ (eds) Glutamic acid: advances in biochemistry and physiology. New York, Raven Press
72.
Heywood R, Worden AN (1972) Glutamate toxicity in laboratory animals. In: Filer LJ Jr, Garattini S, Kare MR, Reynolds WA, Wurtman RJ (eds) Glutamic acid: advances in biochemistry and physiology. New York, Raven Press
73.
Hermanussen M, García AP, Sunder M, Voigt M, Salazar V, Tresguerres JA (2006) Obesity, voracity, and short stature: the impact of glutamate on the regulation of appetite. Eur J Clin Nutr 60(1):25–31PubMedCrossRef
74.
Monno A, Vezzani A, Bastone A, Salmona M, Garattini S (1995) Extracellular glutamate levels in the hypothalamus and hippocampus of rats after acute or chronic oral intake of monosodium glutamate. Neurosci Lett 193(1):45–48PubMedCrossRef
75.
Cheunsuang O, Stewart AL, Morris R (2006) Differential uptake of molecules from the circulation and CSF reveals regional and cellular specialisation in CNS detection of homeostatic signals. Cell Tissue Res 325(2):397–402PubMedCrossRef
76.
Lieth E, Barber AJ, Xu B, Dice C, Ratz MJ, Tanase D, Strother JM (1998) Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State retina research group. Diabetes 47(5):815–820
77.
Kowluru RA, Engerman RL, Case GL, Kern TS (2001) Retinal glutamate in diabetes and effect of antioxidants. Neurochem Int 38(5):385–390PubMedCrossRef
78.
Yu X, Xu Z, Mi M, Xu H, Zhu J, Wei N, Chen K, Zhang Q, Zeng K, Wang J, Chen F, Tang Y (2008) Dietary taurine supplementation ameliorates diabetic retinopathy via anti-excitotoxicity of glutamate in streptozotocin-induced Sprague-Dawley rats. Neurochem Res 33(3):500–507PubMedCrossRef
79.
Zeng K, Xu H, Chen K, Zhu J, Zhou Y, Zhang Q, Mantian M (2010) Effects of taurine on glutamate uptake and degradation in Müller cells under diabetic conditions via antioxidant mechanism. Mol Cell Neurosci 45(2):192–199PubMedCrossRef
80.
Liu MT, Rothstein JD, Gershon MD, Kirchgessner AL (1997) Glutamatergic enteric neurons. J Neurosci 17(12):4764–4784PubMed
81.
Kirchgessner AL, Liu MT, Alcantara F (1997) Excitotoxicity in the enteric nervous system. J Neurosci 17(22):8804–8816PubMed
82.
von Boyen GB, Steinkamp M, Adler G, Kirsch J (2006) Glutamate receptor subunit expression in primary enteric glia cultures. J Recept Signal Transduct Res 26(4):329–336CrossRef
83.
Nasser Y, Keenan CM, Ma AC, McCafferty DM, Sharkey KA (2007) Expression of a functional metabotropic glutamate receptor 5 on enteric glia is altered in states of inflammation. Glia 55(8):859–872PubMedCrossRef
84.
Irving EA, Bamford M (2002) Role of mitogen- and stress-activated kinases in ischemic injury. J Cereb Blood Flow Metab 22(6):631–647PubMedCrossRef
85.
Bush TG, Savidge TC, Freeman TC, Cox HJ, Campbell EA, Mucke L, Johnson MH, Sofroniew MV (1998) Fulminant Jejuno-Ileitis following ablation of enteric glia in adult transgenic mice. Cell 93(2):189–201PubMedCrossRef
86.
Savidge TC, Newman P, Pothoulakis C, Ruhl A, Neunlist M, Bourreille A, Hurst R, Sofroniew MV (2007) Enteric glia regulate intestinal barrier function and inflammation via release of S-nitrosoglutathione. Gastroenterology 132(4):1344–1358PubMedCrossRef
87.
Secondulfo M, Iafusco D, Carratù R, deMagistris L, Sapone A, Generoso M, Mezzogiomo A, Sasso FC, Cartenì M, De Rosa R, Prisco F, Esposito V (2004) Ultrastructural mucosal alterations and increased intestinal permeability in non-celiac, type 1 diabetic patients. Dig Liver Dis 36(1):35–45
88.
Westerholm-Ormio M, Vaarala O, Pihkala P, Ilonen J, Savilahti E (2003) Immunologic activity in the small intestinal mucosa of pediatric patients with type 1 diabetes. Diabetes 52(9):2287–2295PubMedCrossRef
89.
Savilahti E, Ormälä T, Saukkonen T, Sandini-Pohjavuori U, Kantele JM, Arato A, Ilonen J, Akerblom HK (1999) Jejuna of patients with insulin-dependent diabetes mellitus (IDDM) show signs of immune activation. Clin Exp Immunol 116(1):70–77PubMedCrossRef
90.
Kuitunen M, Saukkonen T, Ilonen J, Akerblom HK, Savilahti E (2002) Intestinal permeability to mannitol and lactulose in children with type 1 diabetes with the HLA-DQB1*02 allele. Autoimmunity 35(5):365–368PubMedCrossRef
91.
Bosi E, Molteni L, Radaelli MG, Folini L, Fermo I, Bazzigaluppi E, Piemonti L, Pastore MR, Paroni R (2006) Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia 49(12):2824–2827PubMedCrossRef
92.
Sapone A, de Magistris L, Pietzak M, Clemente MG, Tripathi A, Cucca F, Lampis R, Kryszak D, Cartenì M, Generoso M, Iafusco D, Prisco F, Laghi F, Riegler G, Carratu R, Counts D, Fasano A (2006) Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes 55(5):1443–1449PubMedCrossRef
93.
Graham S, Courtois P, Malaisse WJ, Rozing J, Scott FW, Mowat AM (2004) Enteropathy precedes type 1 diabetes in the BB rat. Gut 53(10):1437–1444PubMedCrossRef
94.
Baylis LL, Rolls ET (1991) Responses of neurons in the primate taste cortex to glutamate. Physiol Behav 49(5):973–979PubMedCrossRef
95.
Rolls ET, Baylis LL (1994) Gustatory, olfactory, and visual convergence within the primate orbitofrontal cortex. J Neurosci 14(9):5437–5452PubMed
96.
Yamaguchi S, Ninomiya K (2000) Umami and food palatability. J Nutr 130(4S suppl):921S–926S
97.
Chaudhari N, Landin AM, Roper SD (2000) A metabotropic glutamate receptor variant functions as a taste receptor. Nat Neurosci 3(2):113–119PubMedCrossRef
98.
Nelson G, Chandrashekar J, Hoon MA, Feng L, Zhao G, Ryba NJ, Zuker CS (2002) An amino-acid taste receptor. Nature 416(6877):199–202PubMedCrossRef
99.
Li X, Staszewski L, Xu H, Durick K, Zoller M, Adler E (2002) Human receptors for sweet and umami taste. Proc Natl Acad Sci USA 99(7):4692–4696PubMedCrossRef
100.
101.
Oya M, Suzuki H, Watanabe Y, Sato M, Tsuboi T (2011) Amino acid taste receptor regulates insulin secretion in pancreatic β-cell line MIN6 cells. Genes Cells 16(5):608–616PubMedCrossRef
102.
Steiner JE, Glaser D, Hawilo ME, Berridge KC (2001) Comparative expression of hedonic impact: affective reactions to taste by human infants and other primates. Neurosci Biobehav Rev 25(1):53–74PubMedCrossRef
103.
Yamaguchi S (1991) Basic properties of umami and effects on humans. Physiol Behav 49(5):833–841PubMedCrossRef
104.
Bellisle F, Monneuse MO, Chabert M, Larue-Achagiotis C, Lanteaume MT, Louis-Sylvestre J (1991) Monosodium glutamate as a palatability enhancer in the European diet. Physiol Behav 49(5):869–873PubMedCrossRef
105.
Yamaguchi S, Takahashi C (1984) Interactions of monosodium glutamate and sodium chloride on saltiness and palatability. J Food Sci 49:82–85CrossRef
106.
Yamaguchi S, Takihashi C (1984) Hedonic functions of monosodium glutamate and four basic taste substances used at various concentration levels in single and complex systems. Agric Biol Chem 48:1077–1081CrossRef
107.
Bellisle F (1998) Effects of monosodium glutamate on human food palatability. Ann N Y Acad Sci 855:438–441PubMedCrossRef
108.
Rogers PJ, Blundell J (1990) Umami and appetite: effects of monosodium glutamate on hunger and food intake in human subjects. Physiol Behav 48:801–804PubMedCrossRef
109.
Schiffman SS (2000) Intensification of sensory properties of foods for the elderly. J Nutr 130(4S suppl):927S–930S
110.
Okiyama A, Beauchamp GK (1998) Taste dimensions of monosodium glutamate (MSG) in a food system: role of glutamate in young American subjects. Physiol Behav 65(1):177–181PubMedCrossRef
111.
Rhodes J, Titherley AC, Norman JA, Wood R, Lord DW (1991) A survey of the monosodium glutamate content of foods and an estimation of the dietary intake of monosodium glutamate. Food Addit Contam 8(5):663–672PubMedCrossRef
112.
Beyreuther K, Biesalski HK, Fernstrom JD, Grimm P, Hammes WP, Heinemann U, Kempski O, Stehle P, Steinhart H, Walker R (2007) Consensus meeting: monosodium glutamate—an update. Eur J Clin Nutr 61(3):304–313PubMedCrossRef
113.
Walker R, Lupien JR (2000) The safety evaluation of monosodium glutamate. J Nutr 130(4S suppl):1049S–1052S
114.
He K, Du S, Xun P, Sharma S, Wang H, Zhai F, Popkin B (2011) Consumption of monosodium glutamate in relation to incidence of overweight in Chinese adults: China health and nutrition survey (CHNS). Am J Clin Nutr 93(6):1328–1336PubMedCrossRef
115.
Shi Z, Luscombe-Marsh ND, Wittert GA, Yuan B, Dai Y, Pan X, Taylor AW (2010) Monosodium glutamate is not associated with obesity or a greater prevalence of weight gain over 5 years: findings from the Jiangsu Nutrition Study of Chinese adults. Br J Nutr 104(3):457–463PubMedCrossRef
116.
He K, Zhao L, Daviglus ML, Dyer AR, Van Horn L, Garside D, Zhu L, Guo D, Wu Y, Zhou B, Stamler J, INTERMAP Cooperative Research Group (2008) Association of monosodium glutamate intake with overweight in Chinese adults: the INTERMAP Study. Obesity 16(8):1875–1880PubMedCrossRef
117.
Hermanussen M, Tresguerres JA (2003) Does high glutamate intake cause obesity? J Pediatr Endocrinol Metab 16(7):965–968PubMedCrossRef
118.
Samuels A (2010) Monosodium glutamate is not associated with obesity or a greater prevalence of weight gain over 5 years: findings from the Jiangsu nutrition study of Chinese adults–comments by Samuels. Br J Nutr 104(11):1729PubMedCrossRef
119.
Janeczko MJ, Stoll B, Chang X, Guan X, Burrin DG (2007) Extensive gut metabolism limits the intestinal absorption of excessive supplemental dietary glutamate loads in infant pigs. J Nutr 137(11):2384–2390PubMed
120.
Blachier F, Guihot-Joubrel G, Vaugelade P, Le Boucher J, Bernard F, Duée P, Cynober L (1999) Portal hyperglutamatemia after dietary supplementation with monosodium glutamate in pigs. Digestion 60(4):349–357PubMedCrossRef
121.
Graham TE, Sgro V, Friars D, Gibala MJ (2000) Glutamate ingestion: the plasma and muscle free amino acid pools of resting humans. Am J Physiol Endocrinol Metab 278(1):E83–E89PubMed
122.
Stegink LD, Filer LJ Jr, Baker GL (1985) Plasma glutamate concentrations in adult subjects ingesting monosodium L-glutamate in consomme. Am J Clin Nutr 42(2):220–225PubMed
123.
Chevassus H, Renard E, Bertrand G, Mourand I, Puech R, Molinier N, Bockaert J, Petit P, Bringer J (2002) Effects of oral monosodium (L)-glutamate on insulin secretion and glucose tolerance in healthy volunteers. Br J Clin Pharmacol 53(6):641–643PubMedCrossRef
124.
Mourtzakis M, Graham TE (2002) Glutamate ingestion and its effects at rest and during exercise in humans. J Appl Physiol 93(4):1251–1259PubMed
125.
Lamb MM, Myers MA, Barriga K, Zimmet PZ, Rewers M, Norris JM (2008) Maternal diet during pregnancy and islet autoimmunity in offspring. Pediatr Diabetes 9:135–141PubMedCrossRef
126.
Virtanen SM, Kenward MG, Erkkola M, Kautiainen S, Kronberg-Kippilä C, Hakulinen T, Ahonen S, Uusitalo L, Niinistö S, Veijola R, Simell O, Ilonen J, Knip M (2006) Age at introduction of new foods and advanced beta cell autoimmunity in young children with HLA-conferred susceptibility to type 1 diabetes. Diabetologia 49(7):1512–1521PubMedCrossRef
127.
Virtanen SM, Takkinen HM, Nevalainen J, Kronberg-Kippilä C, Salmenhaara M, Uusitalo L, Kenward MG, Erkkola M, Veijola R, Simell O, Ilonen J, Knip M (2011) Early introduction of root vegetables in infancy associated with advanced ß-cell autoimmunity in young children with human leukocyte antigen-conferred susceptibility to Type 1 diabetes. Diabet Med 28(8):965–971PubMedCrossRef
128.
Myers M, Zimmet P (2008) Halting the accelerating epidemic of type 1 diabetes. Lancet 371(9626):1730–1731PubMedCrossRef
129.
Martin FL, Ames JM (2001) Formation of Strecker aldehydes and pyrazines in a fried potato model system. J Agric Food Chem 49(8):3885–3892PubMedCrossRef
130.
Ohara-Takada A, Matsuura-Endo C, Chuda Y, Ono H, Yada H, Yoshida M, Kobayashi A, Tsuda S, Takigawa S, Noda T, Yamauchi H, Mori M (2005) Change in content of sugars and free amino acids in potato tubers under short-term storage at low temperature and the effect on acrylamide level after frying. Biosci Biotechnol Biochem 69(7):1232–1238PubMedCrossRef
131.
Jeevanandam M, Ramias L, Schiller WR (1991) Altered plasma free amino acid levels in obese traumatized man. Metabolism 40(4):385–390PubMedCrossRef
132.
Fujinami S, Hijikata Y, Shiozaki Y, Sameshima Y (1990) Profiles of plasma amino acids in fasted patients with various liver diseases. Hepatogastroenterology 37(suppl 2):81–84PubMed
133.
Vannucchi H, Marchini JS, Padovan GJ, dos-Santos JE, Dutra-de-Oliveira JE (1985) Amino acid patterns in the plasma and ascitic fluid of cirrhotic patients. Braz J Med Biol Res 18(4):465–470PubMed
134.
Holm E, Hack V, Tokus M, Breitkreutz R, Babylon A, Dröge W (1997) Linkage between postabsorptive amino acid release and glutamate uptake in skeletal muscle tissue of healthy young subjects, cancer patients, and the elderly. J Mol Med 75(6):454–461PubMedCrossRef
135.
Eck HP, Drings P, Dröge W (1989) Plasma glutamate levels, lymphocyte reactivity and death rate in patients with bronchial carcinoma. J Cancer Res Clin Oncol 115(6):571–574PubMedCrossRef
136.
Dröge W, Eck HP, Betzler M, Näher H (1987) Elevated plasma glutamate levels in colorectal carcinoma patients and in patients with acquired immunodeficiency syndrome (AIDS). Immunobiology 174(4–5):473–479PubMedCrossRef
137.
Eck HP, Frey H, Dröge W (1989) Elevated plasma glutamate concentrations in HIV-1-infected patients may contribute to loss of macrophage and lymphocyte functions. Int Immunol 1(4):367–372PubMedCrossRef
138.
Dröge W, Eck HP, Betzler M, Schlag P, Drings P, Ebert W (1988) Plasma glutamate concentration and lymphocyte activity. J Cancer Res Clin Oncol 114(2):124–128PubMedCrossRef
139.
Aliprandi A, Longoni M, Stanzani L, Tremolizzo L, Vaccaro M, Begni B, Galimberti G, Garofolo R, Ferrarese C (2005) Increased plasma glutamate in stroke patients might be linked to altered platelet release and uptake. J Cereb Blood Flow Metab 25(4):513–519PubMedCrossRef
140.
Tremolizzo L, DiFrancesco JC, Rodriguez-Menendez V, Sirtori E, Longoni M, Cassetti A, Bossi M, El Mestikawy S, Cavaletti G, Ferrarese C (2006) Human platelets express the synaptic markers VGLUT1 and 2 and release glutamate following aggregation. Neurosci Lett 404(3):262–265PubMedCrossRef
141.
Castellanos M, Sobrino T, Pedraza S, Moldes O, Pumar JM, Silva Y, Serena J, García-Gil M, Castillo J, Dávalos A (2008) High plasma glutamate concentrations are associated with infarct growth in acute ischemic stroke. Neurology 71(23):1862–1868PubMedCrossRef
142.
Pampliega O, Domercq M, Villoslada P, Sepulcre J, Rodríguez-Antigüedad A, Matute C (2008) Association of an EAAT2 polymorphism with higher glutamate concentration in relapsing multiple sclerosis. J Neuroimmunol 195(1–2):194–198PubMedCrossRef
143.
Andreadou E, Kapaki E, Kokotis P, Paraskevas GP, Katsaros N, Libitaki G, Zis V, Sfagos C, Vassilopoulos D (2008) Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment. Clin Neurol Neurosurg 110(3):222–226PubMedCrossRef
144.
Andreadou E, Kapaki E, Kokotis P, Paraskevas GP, Katsaros N, Libitaki G, Petropoulou O, Zis V, Sfagos C, Vassilopoulos D (2008) Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis. In Vivo 22(1):137–141PubMed
145.
Iwasaki Y, Ikeda K, Shiojima T, Kobayashi T, Kinoshita M (1994) Different plasma glutamate levels in subtype of amyotrophic lateral sclerosis. Acta Neurol Scand 89(5):404–405PubMedCrossRef
146.
Iwasaki Y, Ikeda K, Shiojima T, Kinoshita M (1992) Increased plasma concentrations of aspartate, glutamate and glycine in Parkinson’s disease. Neurosci Lett 145(2):175–177PubMedCrossRef
147.
Paraskevas GP, Triantafyllou NI, Kapaki E, Limpitaki G, Petropoulou O, Vassilopoulos D (2006) Add-on lamotrigine treatment and plasma glutamate levels in epilepsy: relation to treatment response. Epilepsy Res 70(2–3):184–189PubMedCrossRef
148.
Aldred S, Moore KM, Fitzgerald M, Waring RH (2003) Plasma amino acid levels in children with autism and their families. J Autism Dev Disord 33(1):93–97PubMedCrossRef
149.
Alam Z, Coombes N, Waring RH, Williams AC, Steventon GB (1998) Plasma levels of neuroexcitatory amino acids in patients with migraine or tension headache. J Neurol Sci 156(1):102–106PubMedCrossRef
150.
Mitani H, Shirayama Y, Yamada T, Maeda K, Ashby CR Jr, Kawahara R (2006) Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 30(6):1155–1158PubMedCrossRef
151.
Trang LE, Fürst P, Odebäck AC, Lövgren O (1985) Plasma amino acids in rheumatoid arthritis. Scand J Rheumatol 14(4):393–402PubMedCrossRef
152.
Anfossi G, Russo I, Trovati M (2009) Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis 19(6):440–449PubMedCrossRef
153.
Nieuwdorp M, Stroes ES, Meijers JC, Büller H (2005) Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol 5(2):155–159PubMedCrossRef
154.
Davì G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, Basili S, Ciabattoni G, Patrono C (2003) Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation 107(25):3199–3203PubMedCrossRef
155.
Hu H, Johansson BL, Hjemdahl P, Li N (2004) Exercise-induced platelet and leucocyte activation is not enhanced in well-controlled Type 1 diabetes, despite increased activity at rest. Diabetologia 47(5):853–859PubMedCrossRef
156.
Swaim AF, Field DJ, Fox-Talbot K, Baldwin WM 3rd, Morrell CN (2010) Platelets contribute to allograft rejection through glutamate receptor signaling. J Immunol 185(11):6999–7006PubMedCrossRef
157.
Tolosa L, Caraballo-Miralles V, Olmos G, Lladó J (2011) TNF-α potentiates glutamate-induced spinal cord motoneuron death via NF-κB. Mol Cell Neurosci 46(1):176–186PubMedCrossRef
158.
159.
Jensen MD, Haymond MW (1991) Protein metabolism in obesity: effects of body fat distribution and hyperinsulinemia on leucine turnover. Am J Clin Nutr 53(1):172–176PubMed
160.
Welle S, Barnard RR, Statt M, Amatruda JM (1992) Increased protein turnover in obese women. Metabolism 41(9):1028–1034PubMedCrossRef
161.
Welle S, Statt M, Barnard R, Amatruda J (1994) Differential effect of insulin on whole-body proteolysis and glucose metabolism in normal-weight, obese, and reduced-obese women. Metabolism 43(4):441–445PubMedCrossRef
162.
Chevalier S, Marliss EB, Morais JA, Lamarche M, Gougeon R (2005) Whole-body protein anabolic response is resistant to the action of insulin in obese women. Am J Clin Nutr 82(2):355–365PubMed
163.
Felig P, Marliss E, Cahill GF Jr (1969) Plasma amino acid levels and insulin secretion in obesity. N Engl J Med 281(15):811–816PubMedCrossRef
164.
Gougeon R, Morais JA, Chevalier S, Pereira S, Lamarche M, Marliss EB (2008) Determinants of whole-body protein metabolism in subjects with and without type 2 diabetes. Diabetes Care 31(1):128–133PubMedCrossRef
165.
Marliss EB, Gougeon R (2002) Diabetes mellitus, lipidus et proteinus! Diabetes Care 25(8):1474–1476
166.
Pereira S, Marliss EB, Morais JA, Chevalier S, Gougeon R (2008) Insulin resistance of protein metabolism in type 2 diabetes. Diabetes 57(1):56–63PubMedCrossRef
167.
Hack V, Stütz O, Kinscherf R, Schykowski M, Kellerer M, Holm E, Dröge W (1996) Elevated venous glutamate levels in (pre)catabolic conditions result at least partly from a decreased glutamate transport activity. J Mol Med 74(6):337–343PubMedCrossRef
168.
Bao Y, Zhao T, Wang X, Qiu Y, Su M, Jia W, Jia W (2009) Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers. J Proteome Res 8(4):1623–1630PubMedCrossRef
169.
Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395(6704):763–770PubMedCrossRef
170.
Konstantinides S, Schäfer K, Koschnick S, Loskutoff DJ (2001) Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 108(10):1533–1540PubMed
171.
Ahrén B, Baldwin RM, Havel PJ (2000) Pharmacokinetics of human leptin in mice and rhesus monkeys. Int J Obes Relat Metab Disord 24(12):1579–1585PubMedCrossRef
172.
Shanley LJ, Irving AJ, Harvey J (2001) Leptin enhances NMDA receptor function and modulates hippocampal synaptic plasticity. J Neurosci 21(24):RC186
173.
Moult PR, Harvey J (2009) Regulation of glutamate receptor trafficking by leptin. Biochem Soc Trans 37(6):1364–1368PubMedCrossRef
174.
Tai ES, Tan ML, Stevens RD, Low YL, Muehlbauer MJ, Goh DL, Ilkayeva OR, Wenner BR, Bain JR, Lee JJ, Lim SC, Khoo CM, Shah SH, Newgard CB (2010) Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. Diabetologia 53(4):757–767PubMedCrossRef
175.
Butte NF, Hsu HW, Thotathuchery M, Wong WW, Khoury J, Reeds P (1999) Protein metabolism in insulin-treated gestational diabetes. Diabetes Care 22(5):806–811PubMedCrossRef
176.
Bennet WM, Connacher AA, Jung RT, Stehle P, Rennie MJ (1991) Effects of insulin and amino acids on leg protein turnover in IDDM patients. Diabetes 40(4):499–508PubMedCrossRef
177.
Tessari P, Nosadini R, Trevisan R, De Kreutzenberg SV, Inchiostro S, Duner E, Biolo G, Marescotti MC, Tiengo A, Crepaldi G (1986) Defective suppression by insulin of leucine-carbon appearance and oxidation in type 1, insulin-dependent diabetes mellitus. Evidence for insulin resistance involving glucose and amino acid metabolism. J Clin Invest 77(6):1797–1804
178.
Nair KS, Ford GC, Halliday D (1987) Effect of intravenous insulin treatment on in vivo whole body leucine kinetics and oxygen consumption in insulin-deprived type I diabetic patients. Metabolism 36(5):491–495PubMedCrossRef
179.
Luzi L, Castellino P, Simonson DC, Petrides AS, DeFronzo RA (1990) Leucine metabolism in IDDM. Role of insulin and substrate availability. Diabetes 39(1):38–48
180.
Umpleby AM, Boroujerdi MA, Brown PM, Carson ER, Sönksen PH (1986) The effect of metabolic control on leucine metabolism in type 1 (insulin-dependent) diabetic patients. Diabetologia 29(3):131–141PubMedCrossRef
181.
Nair KS, Halliday D, Matthews DE, Welle SL (1987) Hyperglucagonemia during insulin deficiency accelerates protein catabolism. Am J Physiol 253(2):E208–E213PubMed
182.
Oresic M, Simell S, Sysi-Aho M, Näntö-Salonen K, Seppänen-Laakso T, Parikka V, Katajamaa M, Hekkala A, Mattila I, Keskinen P, Yetukuri L, Reinikainen A, Lähde J, Suortti T, Hakalax J, Simell T, Hyöty H, Veijola R, Ilonen J, Lahesmaa R, Knip M, Simell O (2008) Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 205(13):2975–2984PubMedCrossRef
183.
Velloso LA, Kämpe O, Hallberg A, Christmanson L, Betsholtz C, Karlsson FA (1993) Demonstration of GAD-65 as the main immunogenic isoform of glutamate decarboxylase in type 1 diabetes and determination of autoantibodies using a radioligand produced by eukaryotic expression. J Clin Invest 91(5):2084–2090PubMedCrossRef
184.
Velloso LA, Björk E, Ballagi AE, Funa K, Andersson A, Kämpe O, Karlsson FA, Eizirik DL (1994) Regulation of GAD expression in islets of Langerhans occurs both at the mRNA and protein level. Mol Cell Endocrinol 102(1–2):31–37PubMedCrossRef
185.
Burton AR, Baquet Z, Eisenbarth GS, Tisch R, Smeyne R, Workman CJ, Vignali DA (2010) Central nervous system destruction mediated by glutamic acid decarboxylase-specific CD4+ T cells. J Immunol 184(9):4863–4870PubMedCrossRef
186.
Newsholme P (2001) Why is l-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection? J Nutr 131(9 Suppl):2515S–2522SPubMed
187.
Kvaratskhelia E, Dabrundashvili N, Gagua M, Maisuradze E, Mikeladze D (2008) Glutamate decreases the secretion of IL-10 by peripheral blood lymphocytes in persons with autoimmune thyroiditis. Georgian Med News 164:73–76PubMed
188.
Lenzen S, Drinkgern J, Tiedge M (1996) Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic Biol Med 20(3):463–466PubMedCrossRef
189.
Albrecht P, Lewerenz J, Dittmer S, Noack R, Maher P, Methner A (2010) Mechanisms of oxidative glutamate toxicity: the glutamate/cystine antiporter system xc- as a neuroprotective drug target. CNS Neurol Disord Drug Targets 9(3):373–382PubMed
190.
Nevo U, Golding I, Neumann AU, Schwartz M, Akselrod S (2004) Autoimmunity as an immune defense against degenerative processes: a primary mathematical model illustrating the bright side of autoimmunity. J Theor Biol 227(4):583–592PubMedCrossRef
191.
Hauben E, Roncarolo MG, Nevo U, Schwartz M (2005) Beneficial autoimmunity in Type 1 diabetes mellitus. Trends Immunol 26(5):248–253PubMedCrossRef
192.
Kimpimäki T, Kulmala P, Savola K, Kupila A, Korhonen S, Simell T, Ilonen J, Simell O, Knip M (2002) Natural history of beta-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes recruited from the general population. J Clin Endocrinol Metab 87(10):4572–4579PubMedCrossRef
193.
Cho JH, Chen L, Kim MH, Chow RH, Hille B, Koh DS (2010) Characteristics and functions of {alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors expressed in mouse pancreatic {alpha}-cells. Endocrinology 151(4):1541–1550PubMedCrossRef
194.
Cabrera O, Jacques-Silva MC, Speier S, Yang SN, Köhler M, Fachado A, Vieira E, Zierath JR, Kibbey R, Berman DM, Kenyon NS, Ricordi C, Caicedo A, Berggren PO (2008) Glutamate is a positive autocrine signal for glucagon release. Cell Metab 7(6):545–554PubMedCrossRef
195.
Uehara S, Muroyama A, Echigo N, Morimoto R, Otsuka M, Yatsushiro S, Moriyama Y (2004) Metabotropic glutamate receptor type 4 is involved in autoinhibitory cascade for glucagon secretion by alpha-cells of islet of Langerhans. Diabetes 53(4):998–1006PubMedCrossRef
196.
Müller WA, Faloona GR, Unger RH (1973) Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance. Am J Med 54(1):52–57
197.
Baron AD, Schaeffer L, Shragg P, Kolterman OG (1987) Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36(3):274–283PubMedCrossRef
198.
Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB (1987) Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64(1):106–110PubMedCrossRef
199.
Dunning BE, Gerich JE (2007) The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 28(3):253–283PubMedCrossRef
200.
Starke AA, Erhardt G, Berger M, Zimmermann H (1984) Elevated pancreatic glucagon in obesity. Diabetes 33(3):277–280PubMedCrossRef
201.
Solerte SB, Rondanelli M, Giacchero R, Stabile M, Lovati E, Cravello L, Pontiggia B, Vignati G, Ferrari E, Fioravanti M (1999) Serum glucagon concentration and hyperinsulinemia influence renal haemodynamics and urinary protein loss in normotensive patients with central obesity. In J Obes Relat Metab Disord 23(9):997–1003CrossRef
202.
Weiss R, D’Adamo E, Santoro N, Hershkop K, Caprio S (2011) Basal α-cell up-regulation in obese insulin-resistant adolescents. J Clin Endocrinol Metab 96(1):91–97PubMedCrossRef
203.
Ferrannini E, Muscelli E, Natali A, Gabriel R, Mitrakou A, Flyvbjerg A, Golay A, Hojlund K (2007) The relationship between insulin sensitivity and cardiovascular disease risk (RISC) project Investigators. Association of fasting glucagon and proinsulin concentrations with insulin resistance. Diabetologia 50(11):2342–2347
204.
Asano T, Ninomiya H, Kan K, Yamamoto T, Okumura M (1989) Plasma glucagon response to intravenous alanine in obese and non-obese subjects. Endocrinol Jpn 36(5):767–773PubMedCrossRef
205.
Kamimura D, Ishihara K, Hirano T (2003) IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 149:1–38PubMedCrossRef
206.
Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF (2003) Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European prospective investigation into cancer and nutrition (EPIC)-Potsdam Study. Diabetes 52(3):812–817PubMedCrossRef
207.
Herder C, Haastert B, Müller-Scholze S, Koenig W, Thorand B, Holle R, Wichmann HE, Scherbaum WA, Martin S, Kolb H (2005) Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative health research in the region of Augsburg survey S4 (KORA S4). Diabetes 54(suppl 2):S11–S17PubMedCrossRef
208.
Ellingsgaard H, Ehses JA, Hammar EB, Van Lommel L, Quintens R, Martens G, Kerr-Conte J, Pattou F, Berney T, Pipeleers D, Halban PA, Schuit FC, Donath MY (2008) Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci USA 105(35):13163–13168PubMedCrossRef
209.
Furuta M, Yano H, Zhou A, Rouillé Y, Holst JJ, Carroll R, Ravazzola M, Orci L, Furuta H, Steiner DF (1997) Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci U SA 94(13):6646–6651CrossRef
210.
Furuta M, Zhou A, Webb G, Carroll R, Ravazzola M, Orci L, Steiner DF (2001) Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice. J Biol Chem 276(29):27197–27202PubMedCrossRef
211.
Zhu X, Orci L, Carroll R, Norrbom C, Ravazzola M, Steiner DF (2002) Severe block in processing of proinsulin to insulin accompanied by elevation of des-64, 65 proinsulin intermediates in islets of mice lacking prohormone convertase 1/3. Proc Natl Acad Sci USA 99(16):10299–10304PubMedCrossRef
212.
213.
Furuta M, Carroll R, Martin S, Swift HH, Ravazzola M, Orci L, Steiner DF (1998) Incomplete processing of proinsulin to insulin accompanied by elevation of Des-31, 32 proinsulin intermediates in islets of mice lacking active PC2. J Biol Chem 273(6):3431–3437PubMedCrossRef
214.
Vincent M, Guz Y, Rozenberg M, Webb G, Furuta M, Steiner D, Teitelman G (2003) Abrogation of protein convertase 2 activity results in delayed islet cell differentiation and maturation, increased alpha-cell proliferation, and islet neogenesis. Endocrinology 144(9):4061–4069PubMedCrossRef
215.
Guardado-Mendoza R, Davalli AM, Chavez AO, Hubbard GB, Dick EJ, Majluf-Cruz A, Tene-Perez CE, Goldschmidt L, Hart J, Perego C, Comuzzie AG, Tejero ME, Finzi G, Placidi C, La Rosa S, Capella C, Halff G, Gastaldelli A, DeFronzo RA, Folli F (2009) Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc Natl Acad Sci USA 106(33):13992–13997PubMedCrossRef
216.
Turque N, Plaza S, Radvanyi F, Carriere C, Saule S (1994) Pax-QNR/Pax-6, a paired box- and homeobox-containing gene expressed in neurons, is also expressed in pancreatic endocrine cells. Mol Endocrinol 8(7):929–938PubMedCrossRef
217.
Hayashi M, Yamada H, Uehara S, Morimoto R, Muroyama A, Yatsushiro S, Takeda J, Yamamoto A, Moriyama Y (2003) Secretory granule-mediated co-secretion of L-glutamate and glucagon triggers glutamatergic signal transmission in islets of Langerhans. J Biol Chem 278(3):1966–1974PubMedCrossRef
218.
Selway JL, Moore CE, Mistry R, John Challiss RA, Herbert TP (2011) Molecular mechanisms of muscarinic acetylcholine receptor-stimulated increase in cytosolic free Ca(2+) concentration and ERK1/2 activation in the MIN6 pancreatic beta-cell line. Acta Diabetol Aug 11 [Epub ahead of print] PubMed PMID: 21833779
219.
Molnár E, Váradi A, McIlhinney RA, Ashcroft SJ (1995) Identification of functional ionotropic glutamate receptor proteins in pancreatic beta-cells and in islets of Langerhans. FEBS Lett 371(3):253–257
220.
Muroyama A, Uehara S, Yatsushiro S, Echigo N, Morimoto R, Morita M, Hayashi M, Yamamoto A, Koh DS, Moriyama Y (2004) A novel variant of ionotropic glutamate receptor regulates somatostatin secretion from delta-cells of islets of Langerhans. Diabetes 53(7):1743–1753PubMedCrossRef
221.
Bai L, Zhang X, Ghishan FK (2003) Characterization of vesicular glutamate transporter in pancreatic alpha—and beta -cells and its regulation by glucose. Am J Physiol Gastrointest Liver Physiol 284(5):G808–G814PubMed
222.
Di Cairano ES, Davalli AM, Perego L, Sala S, Sacchi VF, La Rosa S, Finzi G, Placidi C, Capella C, Conti P, Centonze VE, Casiraghi F, Bertuzzi F, Folli F, Perego C (2011) The glial glutamate transporter 1 (GLT1) is expressed by pancreatic beta-cells and prevents glutamate-induced beta-cell death. J Biol Chem 286(16):14007–14018PubMedCrossRef
223.
Federici M, Hribal M, Perego L, Ranalli M, Caradonna Z, Perego C, Usellini L, Nano R, Bonini P, Bertuzzi F, Marlier LN, Davalli AM, Carandente O, Pontiroli AE, Melino G, Marchetti P, Lauro R, Sesti G, Folli F (2001) High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes 50(6):1290–1301PubMedCrossRef
224.
Jeffrey KD, Alejandro EU, Luciani DS, Kalynyak TB, Hu X, Li H, Lin Y, Townsend RR, Polonsky KS, Johnson JD (2008) Carboxypeptidase E mediates palmitate-induced beta-cell ER stress and apoptosis. Proc Natl Acad Sci USA 105(24):8452–8457PubMedCrossRef
225.
Pradhan AD, Manson JE, Meigs JB, Rifai N, Buring JE, Liu S, Ridker PM (2003) Insulin, proinsulin, proinsulin:insulin ratio, and the risk of developing type 2 diabetes mellitus in women. Am J Med 114(6):438–444PubMedCrossRef
226.
Uchida K (2003) 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res 42(4):318–343PubMedCrossRef
227.
Cunha DA, Ladrière L, Ortis F, Igoillo-Esteve M, Gurzov EN, Lupi R, Marchetti P, Eizirik DL, Cnop M (2009) Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes 58(12):2851–2862PubMedCrossRef
228.
Tsunekawa S, Yamamoto N, Tsukamoto K, Itoh Y, Kaneko Y, Kimura T, Ariyoshi Y, Miura Y, Oiso Y, Niki I (2007) Protection of pancreatic beta-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies. J Endocrinol 193(1):65–74PubMedCrossRef
229.
Walter H, Lübben G (2005) Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus. Drugs 65(1):1–13PubMedCrossRef
230.
Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA, Greig NH (2007) Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 203(2):293–301PubMedCrossRef
231.
Harkavyi A, Whitton PS (2010) Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection.Br J Pharmacol 159(3):495–501
232.
233.
Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH (2002) Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302(3):881–888PubMedCrossRef
234.
Romera C, Hurtado O, Mallolas J, Pereira MP, Morales JR, Romera A, Serena J, Vivancos J, Nombela F, Lorenzo P, Lizasoain I, Moro MA (2007) Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection. J Cereb Blood Flow Metab 27(7):1327–1338PubMedCrossRef
235.
Thal SC, Heinemann M, Luh C, Pieter D, Werner C, Engelhard K (2011) Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-γ-independent mechanisms. J Neurotrauma 28(6):983–993PubMedCrossRef
236.
Angehagen M, Ben-Menachem E, Rönnbäck L, Hansson E (2003) Topiramate protects against glutamate- and kainate-induced neurotoxicity in primary neuronal-astroglial cultures. Epilepsy Res 54(1):63–71PubMedCrossRef
237.
Follett PL, Deng W, Dai W, Talos DM, Massillon LJ, Rosenberg PA, Volpe JJ, Jensen FE (2004) Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate. J Neurosci 24(18):4412–4420PubMedCrossRef
238.
Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M (2004) A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes 28(11):1399–1410CrossRef
239.
Toplak H, Hamann A, Moore R, Masson E, Gorska M, Vercruysse F, Sun X, Fitchet M (2007) Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int J Obes 31(1):138–146CrossRef
240.
Stenlo¨f K, Ro¨ssner S, Vercruysse F, Kumar A, Fitchet M, Sjostrom L (2007) Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab 9(3):360–368
241.
Rosenstock J, Hollander P, Gadde KM, Sun X, Strauss R, Leung A (2007) A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care 30(6):1480–1486PubMedCrossRef
242.
Liang Y, Chen X, Osborne M, DeCarlo SO, Jetton TL, Demarest K (2005) Topiramate ameliorates hyperglycaemia and improves glucose-stimulated insulin release in ZDF rats and db/db mice. Diabetes Obes Metab 7(4):360–369PubMedCrossRef
243.
Frigerio F, Chaffard G, Berwaer M, Maechler P (2006) The antiepileptic drug topiramate preserves metabolism-secretion coupling in insulin secreting cells chronically exposed to the fatty acid oleate. Biochem Pharmacol 72(8):965–973PubMedCrossRef
244.
Davalli AM, Perego C, Folli FB, Bosi E (2011) Long-lasting remission of type 1 diabetes following treatment with topiramate for generalized seizures. Acta Diabetol. doi:10.​1007/​s00592-011-0268-y
245.
Evertsen J, Alemzadeh R, Wang X (2009) Increasing incidence of pediatric type 1 diabetes mellitus in Southeastern Wisconsin: relationship with body weight at diagnosis. PLoS One 4(9):e6873PubMedCrossRef
246.
Ljungkrantz M, Ludvigsson J, Samuelsson U (2008) Type 1 diabetes: increased height and weight gains in early childhood. Pediatr Diabetes 9(3):50–56PubMedCrossRef
Metadaten
Titel
The potential role of glutamate in the current diabetes epidemic
verfasst von
Alberto M. Davalli
Carla Perego
Franco B. Folli
Publikationsdatum
01.06.2012
Verlag
Springer Milan
Erschienen in
Acta Diabetologica / Ausgabe 3/2012
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-011-0364-z

Weitere Artikel der Ausgabe 3/2012

Acta Diabetologica 3/2012 Zur Ausgabe

Original Article

White rice vinegar improves pancreatic beta-cell function and fatty liver in streptozotocin-induced diabetic rats

Case Report

Generalized allergy due to zinc in insulin treated with zinc-free insulin

Case Report

Choreoathetosis associated with non-chetotic hyperglycemia

Original Article

Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes

Original Article

Diazoxide inhibits aortic endothelial cell apoptosis in diabetic rats via activation of ERK

Original Article

A cross-sectional survey of depression, anxiety, and cognitive function in patients with type 2 diabetes

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise